Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis.

Abstract : The leishmaniases are protozoal diseases that severely affect large populations in tropical and subtropical regions. There are only limited treatment options and preventative measures. Vaccines will be important for prevention, control and elimination of leishmaniasis, and could reduce the transmission and burden of disease in endemic populations. We report the development of a DNA vaccine against leishmaniasis that induced T cell-based immunity and is a candidate for clinical trials. The vaccine antigens were selected as conserved in various Leishmania species, different endemic regions, and over time. They were tested with T cells from individuals cured of leishmaniasis, and shown to be immunogenic and to induce CD4(+) and CD8(+) T cell responses in genetically diverse human populations of different endemic regions. The vaccine proved protective in a rodent model of infection. Thus, the immunogenicity of candidate vaccine antigens in human populations of endemic regions, as well as proof of principle for induction of specific immune responses and protection against Leishmania infection in mice, provides a viable strategy for T cell vaccine development.
Type de document :
Article dans une revue
Science Translational Medicine, American Association for the Advancement of Science, 2014, 6 (234), pp.234ra56. 〈10.1126/scitranslmed.3008222〉
Liste complète des métadonnées

https://hal-riip.archives-ouvertes.fr/pasteur-01375107
Contributeur : Institut Pasteur Tunis <>
Soumis le : jeudi 25 mai 2017 - 11:44:47
Dernière modification le : samedi 11 août 2018 - 13:34:01

Identifiants

Collections

Citation

Shantanabha Das, Anja Freier, Thouraya Boussoffara, Sushmita Das, Detlef Oswald, et al.. Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis.. Science Translational Medicine, American Association for the Advancement of Science, 2014, 6 (234), pp.234ra56. 〈10.1126/scitranslmed.3008222〉. 〈pasteur-01375107〉

Partager

Métriques

Consultations de la notice

61